Limits...
The Promise of Preventive Cancer Vaccines.

Lollini PL, Cavallo F, Nanni P, Quaglino E - Vaccines (Basel) (2015)

Bottom Line: Years of unsuccessful attempts at fighting established tumors with vaccines have taught us all that they are only able to truly impact patient survival when used in a preventive setting, as would normally be the case for traditional vaccines against infectious diseases.While true primary cancer prevention is still but a long-term goal, secondary and tertiary prevention are already in the clinic and providing encouraging results.A combination of immunopreventive cancer strategies and recently approved checkpoint inhibitors is a further promise of forthcoming successful cancer disease control, but prevention will require a considerable reduction of currently reported toxicities.

View Article: PubMed Central - PubMed

Affiliation: Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Viale Filopanti 22, Bologna 40126, Italy. pierluigi.lollini@unibo.it.

ABSTRACT
Years of unsuccessful attempts at fighting established tumors with vaccines have taught us all that they are only able to truly impact patient survival when used in a preventive setting, as would normally be the case for traditional vaccines against infectious diseases. While true primary cancer prevention is still but a long-term goal, secondary and tertiary prevention are already in the clinic and providing encouraging results. A combination of immunopreventive cancer strategies and recently approved checkpoint inhibitors is a further promise of forthcoming successful cancer disease control, but prevention will require a considerable reduction of currently reported toxicities. These considerations summed with the increased understanding of tumor antigens allow space for an optimistic view of the future.

No MeSH data available.


Related in: MedlinePlus

Schematic representation of the basic principles of checkpoint inhibition. The potential roles of the inhibition of CTLA-4 during the priming of T cells in secondary lymphoid organs and of PD-1 and its ligands (PD-L) during the effector phase in the tumor microenvironment are shown.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494347&req=5

vaccines-03-00467-f002: Schematic representation of the basic principles of checkpoint inhibition. The potential roles of the inhibition of CTLA-4 during the priming of T cells in secondary lymphoid organs and of PD-1 and its ligands (PD-L) during the effector phase in the tumor microenvironment are shown.

Mentions: CTLA-4 and PD-1 inhibitory checkpoint pathways act in temporally and spatially distinct ways in regulating T cell response (Figure 2). CTLA-4 is mainly involved in the priming phase in secondary lymphoid organs, while PD-1 dampens the effector functions of already activated T cells in the periphery [103].


The Promise of Preventive Cancer Vaccines.

Lollini PL, Cavallo F, Nanni P, Quaglino E - Vaccines (Basel) (2015)

Schematic representation of the basic principles of checkpoint inhibition. The potential roles of the inhibition of CTLA-4 during the priming of T cells in secondary lymphoid organs and of PD-1 and its ligands (PD-L) during the effector phase in the tumor microenvironment are shown.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494347&req=5

vaccines-03-00467-f002: Schematic representation of the basic principles of checkpoint inhibition. The potential roles of the inhibition of CTLA-4 during the priming of T cells in secondary lymphoid organs and of PD-1 and its ligands (PD-L) during the effector phase in the tumor microenvironment are shown.
Mentions: CTLA-4 and PD-1 inhibitory checkpoint pathways act in temporally and spatially distinct ways in regulating T cell response (Figure 2). CTLA-4 is mainly involved in the priming phase in secondary lymphoid organs, while PD-1 dampens the effector functions of already activated T cells in the periphery [103].

Bottom Line: Years of unsuccessful attempts at fighting established tumors with vaccines have taught us all that they are only able to truly impact patient survival when used in a preventive setting, as would normally be the case for traditional vaccines against infectious diseases.While true primary cancer prevention is still but a long-term goal, secondary and tertiary prevention are already in the clinic and providing encouraging results.A combination of immunopreventive cancer strategies and recently approved checkpoint inhibitors is a further promise of forthcoming successful cancer disease control, but prevention will require a considerable reduction of currently reported toxicities.

View Article: PubMed Central - PubMed

Affiliation: Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Viale Filopanti 22, Bologna 40126, Italy. pierluigi.lollini@unibo.it.

ABSTRACT
Years of unsuccessful attempts at fighting established tumors with vaccines have taught us all that they are only able to truly impact patient survival when used in a preventive setting, as would normally be the case for traditional vaccines against infectious diseases. While true primary cancer prevention is still but a long-term goal, secondary and tertiary prevention are already in the clinic and providing encouraging results. A combination of immunopreventive cancer strategies and recently approved checkpoint inhibitors is a further promise of forthcoming successful cancer disease control, but prevention will require a considerable reduction of currently reported toxicities. These considerations summed with the increased understanding of tumor antigens allow space for an optimistic view of the future.

No MeSH data available.


Related in: MedlinePlus